Article

A Multifactorial Model of T Cell Expansion and Durable Clinical Benefit in Response to a PD-L1 Inhibitor

2017-12-08

Abstract excerpt

<h4>ABSTRACT</h4> Checkpoint inhibitor immunotherapies have had major success in treating patients with late-stage cancers, yet the minority of patients benefit [1]. Mutation load and PD-L1 staining are leading biomarkers associated with response, but each is an imperfect predictor. A key challenge to predicting response is modeling the interaction between the tumor and immune system. We begin to address this cha...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 24304297-5108-5279-b0a7-fd4152654b1b
DOI: 10.1101/231316

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Multifactorial Model of T Cell Expansion and Durable Clinical Benefit in Response to a PD-L1 InhibitorDOI 10.1101/231316Read

Predicting immunotherapy response in advanced bladder cancer: a meta-analysis of six independent cohortsSemantic proximity Read

Robust prediction of patient outcomes with immune checkpoint blockade therapy for cancer using common clinical, pathologic, and genomic featuresSemantic proximity Read

The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancerSemantic proximity Read

The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer.Semantic proximity Read

Tumor Immune Infiltration as a Predictor of Response to Neoadjuvant Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: An Integrative TCGA AnalysisSemantic proximity Read

Multimodal integration of blood RNA and ctDNA reflects response to immunotherapy in metastatic urothelial cancerSemantic proximity Read

Deep neural network modeling identifies biomarkers of response to immune-checkpoint therapySemantic proximity Read

Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptomeSemantic proximity Read

Generalizable AI predicts immunotherapy outcomes across cancers and treatmentsSemantic proximity Read

Uncovering Predictive Gene and Cellular Signatures for Checkpoint Immunotherapy Response through Machine Learning Analysis of Immune Single-Cell RNA-seq DataSemantic proximity Read

AI-Driven Predictive Biomarker Discovery with Contrastive Learning to Improve Clinical Trial OutcomesSemantic proximity Read

Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model.Semantic proximity Read